Avatopopal maleate is indicated for adult patients with chronic hepatopathy-related thrombocytopenia who undergo elective diagnostic procedures or surgery. Patients with chronic liver disease should not take this product to restore normal platelet count.
*The following content is generated by AI and is for reference only.
Avatrombopag Maleate is a potent, orally active thrombopoietin receptor agonist (TPO-RA) designed to stimulate platelet production in patients with chronic liver disease (CLD) and immune thrombocytopenia (ITP). Chemically identified by its CAS number 1247936-58-0, the compound features a complex molecular structure represented by the formula C29H34N8O4·C4H4O4. This maleate salt form ensures optimal stability and bioavailability for oral administration. Unlike earlier generation TPO-RAs that required subcutaneous injection, Avatrombopag offers the significant clinical advantage of convenient oral dosing, improving patient compliance and quality of life.
The primary therapeutic indication for Avatrombopag involves preparing patients with CLD for planned surgical or invasive procedures. In these cases, the drug effectively raises platelet counts to reduce the risk of bleeding complications, thereby minimizing the need for platelet transfusions. Clinical trials have demonstrated its efficacy in rapidly increasing platelet levels within a short treatment window, typically administered five to nine days before the procedure. Additionally, it has shown promise in managing ITP in adult patients who have had an insufficient response to prior treatments, offering a non-invasive alternative to corticosteroids or splenectomy.
Mechanistically, Avatrombopag binds selectively to the thrombopoietin receptor on megakaryocyte progenitor cells in the bone marrow. This binding mimics the action of endogenous thrombopoietin, promoting proliferation and differentiation into mature megakaryocytes, which subsequently release platelets into circulation. Its unique pharmacokinetic profile allows for dose flexibility based on baseline platelet counts, reducing the risk of excessive thrombosis while maintaining therapeutic efficacy. As a second-generation agent, it exhibits high specificity, potentially lowering the incidence of adverse events associated with off-target effects. With ongoing research expanding its potential applications in various hematologic disorders, Avatrombopag Maleate stands as a critical advancement in hematology, bridging the gap between effective platelet stimulation and patient-centric care delivery.
(All Rights Reserved)
